Matthew Strobeck Acquires 10,000 Shares of QuidelOrtho (NASDAQ:QDEL) Stock

QuidelOrtho Corporation (NASDAQ:QDEL) Director Matthew Strobeck bought 10,000 shares of the company’s stock in a transaction that occurred on Friday, February 13th. The stock was bought at an average price of $23.96 per share, for a total transaction of $239,600.00. Following the acquisition, the director directly owned 27,775 shares of the company’s stock, valued at $665,489. The trade was a 56.26% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

QuidelOrtho Stock Performance

Shares of QDEL opened at $23.58 on Friday. The firm has a market capitalization of $1.60 billion, a P/E ratio of -1.42 and a beta of 0.68. The company has a debt-to-equity ratio of 1.29, a current ratio of 1.50 and a quick ratio of 0.98. QuidelOrtho Corporation has a one year low of $19.50 and a one year high of $42.50. The business has a fifty day moving average of $29.56 and a 200 day moving average of $27.72.

QuidelOrtho (NASDAQ:QDEL) last posted its earnings results on Wednesday, February 11th. The company reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.03. The company had revenue of $723.60 million for the quarter, compared to the consensus estimate of $699.80 million. QuidelOrtho had a positive return on equity of 5.91% and a negative net margin of 41.46%.QuidelOrtho’s revenue was up 2.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.63 earnings per share. As a group, sell-side analysts anticipate that QuidelOrtho Corporation will post 2.3 EPS for the current year.

Institutional Trading of QuidelOrtho

Several institutional investors have recently made changes to their positions in the business. Allianz Asset Management GmbH lifted its position in QuidelOrtho by 98.6% during the third quarter. Allianz Asset Management GmbH now owns 463,223 shares of the company’s stock valued at $13,642,000 after purchasing an additional 229,938 shares during the last quarter. Ballast Asset Management LP lifted its holdings in shares of QuidelOrtho by 217.7% in the 3rd quarter. Ballast Asset Management LP now owns 80,019 shares of the company’s stock valued at $2,357,000 after acquiring an additional 54,829 shares during the last quarter. Rhumbline Advisers grew its position in QuidelOrtho by 34.3% in the second quarter. Rhumbline Advisers now owns 173,267 shares of the company’s stock worth $4,994,000 after acquiring an additional 44,242 shares in the last quarter. Rice Hall James & Associates LLC bought a new stake in QuidelOrtho during the third quarter worth approximately $7,625,000. Finally, Lightrock Netherlands B.V. increased its stake in QuidelOrtho by 27.8% during the second quarter. Lightrock Netherlands B.V. now owns 466,000 shares of the company’s stock worth $13,430,000 after acquiring an additional 101,423 shares during the last quarter. Hedge funds and other institutional investors own 99.00% of the company’s stock.

QuidelOrtho News Roundup

Here are the key news stories impacting QuidelOrtho this week:

• Positive Sentiment: CEO Brian Blaser purchased 10,540 shares (~$23.59 avg), increasing his stake by ~35.7% — a strong insider vote of confidence from the CEO. CEO Form 4
• Positive Sentiment: Director Matthew Strobeck bought 10,000 shares (~$23.96 avg), increasing his stake substantially — another internal signal supporting management’s view of value. Director Form 4
• Positive Sentiment: CFO Joseph Busky also bought 3,370 shares (~$23.66 avg), a meaningful increase in his ownership. Insider buys from multiple officers can signal confidence in longer-term prospects. CFO Form 4
• Neutral Sentiment: Q4 results beat consensus: EPS $0.46 vs. $0.43 and revenue $723.6M vs. $699.8M — top-line strength was driven by Labs and global growth. This is supportive but not enough to offset other headwinds. Zacks: Q4 Earnings Beat
• Neutral Sentiment: Company outlined a 2026 revenue target of $2.7B–$2.9B and emphasized R&D pipeline progress — positive for long-term growth, but investors are focused on near-term profitability and execution. Seeking Alpha: 2026 Revenue Target
• Negative Sentiment: FY2026 guidance came in light: EPS $2.00–$2.42 vs. consensus ~ $2.49 and revenue guidance $2.7B–$2.9B vs. ~$2.8B consensus — the EPS range disappointed investors and likely drove most of the selling pressure. AAII: Why QDEL Is Down
• Negative Sentiment: Margins compressed in Q4 and management cited respiratory weakness weighing on profitability — margin recovery is central to meeting upside expectations and was highlighted in negative market commentary. Yahoo: Q4 Deep Dive
• Negative Sentiment: Planned retirement of the CFO was announced (timing/succession details matter); leadership changes in finance can create near-term uncertainty until a successor is named. TipRanks: CFO Retirement

Analysts Set New Price Targets

A number of analysts have commented on QDEL shares. UBS Group set a $30.00 target price on shares of QuidelOrtho in a report on Thursday. Zacks Research upgraded QuidelOrtho from a “strong sell” rating to a “hold” rating in a research note on Tuesday, January 13th. JPMorgan Chase & Co. decreased their target price on QuidelOrtho from $26.00 to $22.00 and set an “underweight” rating on the stock in a report on Friday, November 7th. Citigroup lifted their target price on QuidelOrtho from $23.00 to $30.00 and gave the company a “neutral” rating in a research report on Thursday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of QuidelOrtho in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $31.50.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.